{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T14:28:20Z","timestamp":1793284100388,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T00:00:00Z","timestamp":1635465600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychiatric Research"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.jpsychires.2021.10.027","type":"journal-article","created":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T13:28:28Z","timestamp":1634822908000},"page":"241-246","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Site-independent confirmation of primary site-based PANSS ratings in a schizophrenia trial"],"prefix":"10.1016","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1054-5197","authenticated-orcid":false,"given":"Steven D.","family":"Targum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6480-859X","authenticated-orcid":false,"given":"Christopher","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Breier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0922-5970","authenticated-orcid":false,"given":"Stephen K.","family":"Brannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpsychires.2021.10.027_bib1","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013"},{"issue":"5","key":"10.1016\/j.jpsychires.2021.10.027_bib2","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1093\/schbul\/sbaa036","article-title":"Burying our heads in the sand: the neglected importance of reporting inter-rater reliability in antipsychotic medication trials","volume":"46","author":"Berendsen","year":"2020","journal-title":"Schizophr. Bull."},{"issue":"4","key":"10.1016\/j.jpsychires.2021.10.027_bib3","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/archneur.1997.00550160091022","article-title":"Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease","volume":"54","author":"Bodick","year":"1997","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jpsychires.2021.10.027_bib4","first-page":"77","article-title":"Xanomeline plus trospium: a novel strategy to enhance pro-muscarinic efficacy and mitigate peripheral side effects. ACNP 57th Annual Meeting: poster Session I","volume":"43","author":"Brannan","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpsychires.2021.10.027_bib5","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa2017015","article-title":"Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia","volume":"384","author":"Brannan","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.jpsychires.2021.10.027_bib6","doi-asserted-by":"crossref","first-page":"B16","DOI":"10.1016\/j.clinthera.2011.11.016","article-title":"Quantifying clinical relevance in the treatment of schizophrenia","volume":"33","author":"Correll","year":"2011","journal-title":"Clin. Therapeut."},{"key":"10.1016\/j.jpsychires.2021.10.027_bib7","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1034\/j.1600-0447.107.s416.5.x","article-title":"The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia","volume":"Suppl","author":"Haro","year":"2003","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.jpsychires.2021.10.027_bib8","series-title":"Poster Presented at American Society of Clinical Psychopharmacology","article-title":"Xanomeline plus trospium: a novel strategy to enhance pro-muscarinic efficacy and mitigate peripheral side effects","author":"Kavoussi","year":"2017"},{"key":"10.1016\/j.jpsychires.2021.10.027_bib9","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jpsychires.2021.10.027_bib10","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1038\/sj.npp.1301325","article-title":"Defining 'response' in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs","volume":"32","author":"Leucht","year":"2007","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.jpsychires.2021.10.027_bib11","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/schbul\/sbq016","article-title":"The PANSS should be rescaled","volume":"36","author":"Leucht","year":"2010","journal-title":"Schizophr. Bull."},{"issue":"1\u20132","key":"10.1016\/j.jpsychires.2021.10.027_bib12","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s12031-002-0031-5","article-title":"The utility of muscarinic agonists in the treatment of Alzheimer's disease","volume":"19","author":"Messer","year":"2002","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.jpsychires.2021.10.027_bib13","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/00004714-200206000-00013","article-title":"Effects of interrater reliability of psychopathologic assessment on power and sample size calculations in clinical trials","volume":"22","author":"Muller","year":"2002","journal-title":"J. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.jpsychires.2021.10.027_bib14","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/schbul\/sbp124","article-title":"Should the PANSS be rescaled?","volume":"36","author":"Obermeier","year":"2010","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jpsychires.2021.10.027_bib15","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s11934-003-0023-1","article-title":"Trospium chloride: a quaternary amine with unique pharmacologic properties","volume":"4","author":"Pak","year":"2003","journal-title":"Curr. Urol. Rep."},{"key":"10.1016\/j.jpsychires.2021.10.027_bib16","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults","volume":"168","author":"Posner","year":"2011","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.jpsychires.2021.10.027_bib17","series-title":"SAS\/ACCESS\u00ae 9.4 Interface to ADABAS: Reference","author":"SAS Institute Inc","year":"2013"},{"key":"10.1016\/j.jpsychires.2021.10.027_bib18","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0022-3565(25)38667-2","article-title":"Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors","volume":"269","author":"Shannon","year":"1994","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"Suppl. 20","key":"10.1016\/j.jpsychires.2021.10.027_bib19","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J. Clin. Psychiatr."},{"issue":"8","key":"10.1016\/j.jpsychires.2021.10.027_bib20","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1176\/appi.ajp.2008.06091591","article-title":"Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia","volume":"165","author":"Shekhar","year":"2008","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.jpsychires.2021.10.027_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2019.100317","article-title":"Audio-digital recordings for surveillance in clinical trials of Major Depressive Disorder","author":"Targum","year":"2019","journal-title":"Contempor. Clin. Trials Commun."},{"key":"10.1016\/j.jpsychires.2021.10.027_bib22","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/j.euroneuro.2014.08.016","article-title":"Audio-digital recordings used for independent confirmation of site-based MADRS interview scores","volume":"24","author":"Targum","year":"2014","journal-title":"Eur. Neuropsychopharmacol"},{"issue":"3","key":"10.1016\/j.jpsychires.2021.10.027_bib23","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.euroneuro.2014.11.023","article-title":"Impact of interview length on ratings reliability in a schizophrenia trial","volume":"25","author":"Targum","year":"2015","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.jpsychires.2021.10.027_bib24","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jpsychires.2019.01.017","article-title":"Comparability of blinded remote and site-based assessments of response to esketamine or placebo nasal spray in patients with treatment resistant depression","volume":"111","author":"Targum","year":"2019","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jpsychires.2021.10.027_bib25","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.schres.2021.05.004","article-title":"Audio-digital recordings to assess ratings reliability in clinical trials of schizophrenia","volume":"232","author":"Targum","year":"2021","journal-title":"Schizophr. Res."}],"container-title":["Journal of Psychiatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395621006245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395621006245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T11:24:24Z","timestamp":1758367464000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022395621006245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":25,"alternative-id":["S0022395621006245"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychires.2021.10.027","relation":{},"ISSN":["0022-3956"],"issn-type":[{"value":"0022-3956","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Site-independent confirmation of primary site-based PANSS ratings in a schizophrenia trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Psychiatric Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpsychires.2021.10.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}